ATE65403T1 - Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. - Google Patents

Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.

Info

Publication number
ATE65403T1
ATE65403T1 AT87100811T AT87100811T ATE65403T1 AT E65403 T1 ATE65403 T1 AT E65403T1 AT 87100811 T AT87100811 T AT 87100811T AT 87100811 T AT87100811 T AT 87100811T AT E65403 T1 ATE65403 T1 AT E65403T1
Authority
AT
Austria
Prior art keywords
human
promoting
csf
haematopoietic
restoration
Prior art date
Application number
AT87100811T
Other languages
English (en)
Inventor
Masahiko Tamura
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11745897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE65403(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE65403T1 publication Critical patent/ATE65403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87100811T 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. ATE65403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1028086 1986-01-22
EP87100811A EP0230980B2 (de) 1986-01-22 1987-01-21 Pharmazeutischer Stoff für die Förderung der Wiederherstellung der hämatopoietischen Fähigkeit

Publications (1)

Publication Number Publication Date
ATE65403T1 true ATE65403T1 (de) 1991-08-15

Family

ID=11745897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87100811T ATE65403T1 (de) 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.

Country Status (5)

Country Link
EP (1) EP0230980B2 (de)
AT (1) ATE65403T1 (de)
CA (1) CA1297004C (de)
DE (1) DE3771509D1 (de)
ES (1) ES2039209T5 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0565722A1 (de) * 1990-12-25 1993-10-20 Kyowa Hakko Kogyo Co., Ltd. Pharmazeutische zubereitung zur pernasalen verabreichung
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0953354A4 (de) 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co Hämatopoietische stammzellen proliferierende wirkstoffe
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
EP2426139B1 (de) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4-Antagonisten und Verwendung davon
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
CA2673719C (en) 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
DE102014001250C5 (de) 2014-02-03 2021-07-29 Carl Freudenberg Kg Fensterwischer
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) * 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.

Also Published As

Publication number Publication date
ES2039209T5 (es) 1996-07-16
EP0230980B1 (de) 1991-07-24
DE3771509D1 (de) 1991-08-29
CA1297004C (en) 1992-03-10
EP0230980A3 (en) 1988-07-27
EP0230980A2 (de) 1987-08-05
ES2039209T3 (es) 1993-09-16
EP0230980B2 (de) 1996-03-20

Similar Documents

Publication Publication Date Title
ATE65403T1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DE3683430D1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
OA09317A (fr) "Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des leucémies".
DK12990D0 (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
IT8767494A0 (it) Composizione liquida per il trattamento preventivo e curativo di malattie crittogamiche di tipo oidio e procedimento per la messa in opera di tale composizione
NO873437L (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.
ES8603270A1 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
ATA269387A (de) Pharmazeutisches mittel zur förderung und stimulierung des haarwachstums und zur verringerung von haarausfall auf basis von pyrimidinderivaten, sowie verwendung des mittels
DE69919969D1 (de) Humanes Wachstumshormon zur Stimulierung der Hämatopoese und der Immunrekonstitution nach hämatopoetischer Stammzelltransplantation beim Menschen
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE206056T1 (de) Therapeutisches agens für neutropenie
KR100908628B1 (ko) Ｇ-ｃｓｆ를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물
JPS5559111A (en) Biological medicine for stimulating life activity of vital body and its manufacture
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
ATE65404T1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis- faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
IT8220835A0 (it) Preparazione di soluzioni iniettabili di actinina impiegabili nella terapia umana come antalgico per il trattamento del dolore da neoplasie ed altre affezioni.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time